Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | AHCY | P23526 | 4/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | AHCYL1 | O43865 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10392960 | 1.00 | CDA (0.60) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL14853915 | 1.00 | CDA (0.60) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL18573820 | 1.00 | CDA (0.60) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL14544403 | 0.87 | LMNA (0.49) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL13664021 | 0.87 | LMNA (0.49) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL21276461 | 0.81 | LMNA (0.44) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL15305445 | 0.81 | LMNA (0.44) | CDALMNATHRBMTORMDM2 | |
| SCHEMBL14929318 | 0.78 | POLG (0.53) | — | |
| SCHEMBL14946342 | 0.78 | POLG (0.53) | — | |
| SCHEMBL18573821 | 0.78 | POLG (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | CDA 28/4885LMNA 585/4885THRB 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.